Compare Dr. Reddys with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs CADILA HEALTHCARE - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB CADILA HEALTHCARE DR. REDDYS LAB/
CADILA HEALTHCARE
 
P/E (TTM) x 21.4 14.1 151.2% View Chart
P/BV x 3.2 2.8 116.0% View Chart
Dividend Yield % 0.7 1.5 49.7%  

Financials

 DR. REDDYS LAB   CADILA HEALTHCARE
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
CADILA HEALTHCARE
Mar-18
DR. REDDYS LAB/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs2,875558 515.2%   
Low Rs1,888362 522.3%   
Sales per share (Unadj.) Rs930.2116.3 799.9%  
Earnings per share (Unadj.) Rs117.417.9 657.2%  
Cash flow per share (Unadj.) Rs185.823.1 803.1%  
Dividends per share (Unadj.) Rs20.003.50 571.4%  
Dividend yield (eoy) %0.80.8 110.3%  
Book value per share (Unadj.) Rs844.485.4 988.6%  
Shares outstanding (eoy) m166.071,023.74 16.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.64.0 64.8%   
Avg P/E ratio x20.325.7 78.8%  
P/CF ratio (eoy) x12.819.9 64.5%  
Price / Book Value ratio x2.85.4 52.4%  
Dividend payout %17.019.6 87.0%   
Avg Mkt Cap Rs m395,496470,664 84.0%   
No. of employees `00022.011.8 185.9%   
Total wages/salary Rs m33,56218,545 181.0%   
Avg. sales/employee Rs Th7,032.810,072.7 69.8%   
Avg. wages/employee Rs Th1,527.91,569.1 97.4%   
Avg. net profit/employee Rs Th887.71,547.7 57.4%   
INCOME DATA
Net Sales Rs m154,482119,049 129.8%  
Other income Rs m3,3751,132 298.1%   
Total revenues Rs m157,857120,181 131.3%   
Gross profit Rs m31,78228,475 111.6%  
Depreciation Rs m11,3485,388 210.6%   
Interest Rs m889911 97.6%   
Profit before tax Rs m22,92023,308 98.3%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,8585,644 68.4%   
Profit after tax Rs m19,50018,292 106.6%  
Gross profit margin %20.623.9 86.0%  
Effective tax rate %16.824.2 69.5%   
Net profit margin %12.615.4 82.2%  
BALANCE SHEET DATA
Current assets Rs m111,10182,005 135.5%   
Current liabilities Rs m58,97360,720 97.1%   
Net working cap to sales %33.717.9 188.7%  
Current ratio x1.91.4 139.5%  
Inventory Days Days7973 108.5%  
Debtors Days Days9498 95.8%  
Net fixed assets Rs m101,24583,703 121.0%   
Share capital Rs m8301,024 81.1%   
"Free" reserves Rs m139,40686,421 161.3%   
Net worth Rs m140,23687,445 160.4%   
Long term debt Rs m22,00025,551 86.1%   
Total assets Rs m224,656180,653 124.4%  
Interest coverage x26.826.6 100.7%   
Debt to equity ratio x0.20.3 53.7%  
Sales to assets ratio x0.70.7 104.3%   
Return on assets %9.110.6 85.4%  
Return on equity %13.920.9 66.5%  
Return on capital %14.922.0 68.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67342,683 207.7%   
Fx outflow Rs m19,10411,242 169.9%   
Net fx Rs m69,56931,441 221.3%   
CASH FLOW
From Operations Rs m28,7049,193 312.2%  
From Investments Rs m-7,727-9,737 79.4%  
From Financial Activity Rs m-21,326515 -4,141.0%  
Net Cashflow Rs m-314-29 1,082.8%  

Share Holding

Indian Promoters % 25.5 74.8 34.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 8.3 65.1%  
FIIs % 35.3 5.9 598.3%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 11.0 139.1%  
Shareholders   75,885 44,069 172.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ALKEM LABORATORIES  PLETHICO PHARMA  FDC LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare DR. REDDYS LAB With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bajaj Finance and ICICI Bank Top Gainers(12:30 pm)

Stock markets in India are presently trading on a positive note. The BSE Sensex is trading up by 90 points and the NSE Nifty is trading up by 35 points.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Oct 16, 2019 02:31 PM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS